“Since the discovery of the JAK2 mutation in 2005, there has been tremendous excitement about the development of selective JAK2 inhibitors as a new treatment for MPNs. After six years of waiting, several drugs are in advanced clinical trials and one may soon be available for patients. Given these new drugs and other lines of clinical investigation, there are many reasons to be optimistic about the prospects for a cure.” - John Crispino, PhD, Northwestern Memorial Hospital, Scientific Advisor for MPN Research Foundation